DMK Pharmaceuticals Regains Full Rights to Commercialize ZIMHI
21 déc. 2023 08h15 HE
|
DMK Pharmaceuticals Corporation
SAN DIEGO, Dec. 21, 2023 (GLOBE NEWSWIRE) -- DMK Pharmaceuticals Corporation (Nasdaq: DMK) (“DMK”), a commercial stage neuro-biotech company primarily focused on developing and commercializing...
DMK Pharmaceuticals Regains Full Rights from US WorldMeds for SYMJEPI® and Provides Corporate Update
28 nov. 2023 08h05 HE
|
DMK Pharmaceuticals Corporation
SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- DMK Pharmaceuticals Corporation (NASDAQ: DMK), a commercial stage neuro-biotech company primarily focused on developing and commercializing products for...
DMK Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
14 nov. 2023 07h30 HE
|
DMK Pharmaceuticals Corporation
Rebranded company to DMK Pharmaceuticals and appointed inaugural, passionate and committed leadership team to execute on new strategy to reduce opioid related deaths through enhanced sales of ZIMHI®...
DMK Pharmaceuticals Announces Presentation of Preclinical Results Comparing Effects of DPI-125 on Opioid Withdrawal Behaviors Versus Standard of Care for Opioid Use Disorder at SfN Neuroscience 2023
13 nov. 2023 10h52 HE
|
DMK Pharmaceuticals Corporation
SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- DMK Pharmaceuticals Corporation (NASDAQ: DMK), a commercial stage neuro-biotech company primarily focused on developing and commercializing products for...
DMK Pharmaceuticals Announces Inducement Option Grant Under Nasdaq Listing Rule 5635(c)(4)
30 oct. 2023 07h30 HE
|
DMK Pharmaceuticals Corporation
SAN DIEGO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- DMK Pharmaceuticals Corporation (NASDAQ: DMK), a commercial-stage biopharmaceutical company, today announced that the compensation committee of the board...
DMK Pharmaceuticals Announces Inducement Option Grant Under Nasdaq Listing Rule 5635(c)(4)
20 oct. 2023 16h15 HE
|
DMK Pharmaceuticals Corporation
SAN DIEGO, Oct. 20, 2023 (GLOBE NEWSWIRE) -- DMK Pharmaceuticals Corporation (NASDAQ: DMK), a commercial-stage biopharmaceutical company, today announced that the compensation committee of the board...
DMK Pharmaceuticals Restructures Executive Team to Support Next Phase of Growth
19 oct. 2023 16h05 HE
|
DMK Pharmaceuticals Corporation
Seth Cohen is appointed Chief Financial Officer, bringing over thirty years of financial industry experience to DMK, and seasoned corporate lawyer John Dorbin assumes role of General Counsel Corporate...
Adamis Pharmaceuticals Changes Name to DMK Pharmaceuticals to Reflect New Strategic Focus
07 sept. 2023 12h00 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the company changed its name to DMK...
Adamis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
21 août 2023 09h15 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced financial results for the second...
Adamis Pharmaceuticals Announces Closing of $8.0 Million Public Offering
04 août 2023 13h43 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the closing of its public offering of...